Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life‑Threatening COVID‑19 Pneumonia

ABSTRACT: Autoantibodies (auto-Abs) neutralizing type I interferons (IFNs) are found in the blood of at least 15% of unvaccinated patients with life-threatening COVID-19 pneumonia. We report here the presence of auto-Abs neutralizing type I IFNs in the bronchoalveolar lavage (BAL) of 54 of the 415 u...

Full description

Autores:
Arias Sierra, Andrés Augusto
Adle Biassette, Homa
Bastard, Paul
Blaize, Marion
Borie, Raphael
Bizien, Lucy
Casanova, Jean Laurent
Cobat, Aurélie
Crestani, Bruno
Conil, Clément
Desmons, Aurore
Duitman, Jan Willem
Edouard Luyt, Charles
Fekkar, Arnaud
Gervais, Adrian
Hammadi, Boualem
Jeljeli, Maxime
Jouanguy, Emmanuelle
Le Voyer, Tom
Migaud, Mélanie
Megarbane, Bruno
Marchal, Astrid
Puel, Anne
Qian, Zhang
Philippot, Quentin
Romano, Alessia
Rosain, Jérémie
Sene, Damien
Zhang, Qian
Mayaux, Julien
Lieuwe D. J., Bos
Tipo de recurso:
Article of investigation
Fecha de publicación:
2023
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/43127
Acceso en línea:
https://hdl.handle.net/10495/43127
Palabra clave:
Autoanticuerpos
Autoantibodies
Lavado Broncoalveolar
Bronchoalveolar Lavage
COVID-19
Interferón Tipo I
Interferon Type I
Interferón-alfa
Interferon-alpha
https://id.nlm.nih.gov/mesh/D001323
https://id.nlm.nih.gov/mesh/D018893
https://id.nlm.nih.gov/mesh/D000086382
https://id.nlm.nih.gov/mesh/D007370
https://id.nlm.nih.gov/mesh/D016898
Rights
openAccess
License
http://creativecommons.org/licenses/by/2.5/co/
Description
Summary:ABSTRACT: Autoantibodies (auto-Abs) neutralizing type I interferons (IFNs) are found in the blood of at least 15% of unvaccinated patients with life-threatening COVID-19 pneumonia. We report here the presence of auto-Abs neutralizing type I IFNs in the bronchoalveolar lavage (BAL) of 54 of the 415 unvaccinated patients (13%) with life-threatening COVID-19 pneumonia tested. The 54 individuals with neutralizing auto-Abs in the BAL included 45 (11%) with auto-Abs against IFN-α2, 37 (9%) with auto-Abs against IFN-ω, 54 (13%) with auto-Abs against IFN-α2 and/or ω, and five (1%) with auto-Abs against IFN-β, including three (0.7%) with auto-Abs neutralizing IFN-α2, IFN-ω, and IFN-β, and two (0.5%) with auto-Abs neutralizing IFN-α2 and IFN-β. Auto-Abs against IFN-α2 also neutralize the other 12 subtypes of IFN-α. Paired plasma samples were available for 95 patients. All seven patients with paired samples who had detectable auto-Abs in BAL also had detectable auto-Abs in plasma, and one patient had auto-Abs detectable only in blood. Auto-Abs neutralizing type I IFNs are, therefore, present in the alveolar space of at least 10% of patients with life-threatening COVID-19 pneumonia. These findings suggest that these auto-Abs impair type I IFN immunity in the lower respiratory tract, thereby contributing to hypoxemic COVID-19 pneumonia.